A microfluidic device — a transparent slab the size of a USB stick — lined with living human cells and engineered to reproduce key organ functions: flow, mechanical forces like breathing, tissue-to-tissue interfaces. It lets researchers ask human-relevant questions without animals.
The landmark device was the 2010 lung-on-a-chip from Donald Ingber's group at Harvard's Wyss Institute, with Dongeun Huh as first author, published in Science. The credited timeline is on The Research page.
Species differ in metabolism, receptor pharmacology and immunity. Analyses of clinical attrition put the failure rate of candidates entering human trials at around 90% — mostly efficacy and toxicity problems animal studies did not predict.
Signed in December 2022, it removed the blanket pre-trial animal-testing mandate, letting developers support applications with alternatives including organ-chip data. In April 2025 the FDA published a roadmap to phase out animal testing for monoclonal antibodies and other drugs, naming organ-chips explicitly.
The best-known vendors are Emulate (Wyss Institute spin-out, 2014) and CN Bio (University of Oxford spin-out, PhysioMimix platform) — general-purpose organ mimics for drug screening.
None of the commercial platforms we are aware of is designed around peptide testing or the peptide–stem-cell interplay. PepStemChip is Panacea Bio Chem's platform for that gap.
Bogdan Dicoias — biochemist and amino acid chain designer, Director of Panacea Bio Chem Ltd. It grows out of Panacea's peptide design, formulation and lyophilization programmes.
No — this site describes the gap it fills, not the blueprint. Architecture, materials and operating parameters remain Panacea intellectual property pending peer review, and no performance figures are claimed here.
Not today. Chips answer specific human-relevant questions better than animals in a growing number of contexts, but whole-body questions still need complementary methods. The field's ethic descends from Russell and Burch's 3Rs: replace, reduce, refine.